LYRA THERAPEUTICS INC (LYRA) Stock Overview
NASDAQ:LYRA - US55234L1052 - Common Stock
LYRA Key Statistics, Chart & Performance
The current stock price of LYRA is 7.025 USD. In the past month the price increased by 0.79%. In the past year, price decreased by -56.33%.
LYRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.46 | 694.86B | ||
| JNJ | JOHNSON & JOHNSON | 17.68 | 425.77B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.47 | 250.79B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18 | 247.82B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.34 | 245.64B | ||
| MRK | MERCK & CO. INC. | 10.92 | 209.99B | ||
| PFE | PFIZER INC | 7.4 | 142.54B | ||
| SNY | SANOFI-ADR | 11.34 | 122.22B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.08 | 96.95B | ||
| GSK | GSK PLC-SPON ADR | 8.83 | 80.45B | ||
| ZTS | ZOETIS INC | 24.98 | 68.86B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 49.53 | 46.93B |
Related stock screener links
About LYRA
Company Profile
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2020-05-01. The firm is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The firm is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).
Company Info
LYRA THERAPEUTICS INC
480 Arsenal Way
Watertown MASSACHUSETTS 02472 US
CEO: Maria Palasis
Employees: 30
Phone: 16173734600
LYRA THERAPEUTICS INC / LYRA FAQ
What is the stock price of LYRA THERAPEUTICS INC today?
The current stock price of LYRA is 7.025 USD. The price decreased by -2.29% in the last trading session.
What is the ticker symbol for LYRA THERAPEUTICS INC stock?
The exchange symbol of LYRA THERAPEUTICS INC is LYRA and it is listed on the Nasdaq exchange.
On which exchange is LYRA stock listed?
LYRA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LYRA THERAPEUTICS INC stock?
9 analysts have analysed LYRA and the average price target is 23.46 USD. This implies a price increase of 233.95% is expected in the next year compared to the current price of 7.025. Check the LYRA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LYRA THERAPEUTICS INC worth?
LYRA THERAPEUTICS INC (LYRA) has a market capitalization of 11.52M USD. This makes LYRA a Nano Cap stock.
How many employees does LYRA THERAPEUTICS INC have?
LYRA THERAPEUTICS INC (LYRA) currently has 30 employees.
What are the support and resistance levels for LYRA THERAPEUTICS INC (LYRA) stock?
LYRA THERAPEUTICS INC (LYRA) has a support level at 6.58 and a resistance level at 7.03. Check the full technical report for a detailed analysis of LYRA support and resistance levels.
Is LYRA THERAPEUTICS INC (LYRA) expected to grow?
The Revenue of LYRA THERAPEUTICS INC (LYRA) is expected to decline by -50.07% in the next year. Check the estimates tab for more information on the LYRA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy LYRA THERAPEUTICS INC (LYRA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LYRA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LYRA, evaluating the profitability, health, valuation and growth aspects
- LYRA THERAPEUTICS INC (LYRA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LYRA THERAPEUTICS INC (LYRA) Sales and EPS estimates to see what analysts future expectations are.
- LYRA THERAPEUTICS INC (LYRA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LYRA THERAPEUTICS INC (LYRA) Insider and Institutional Ownership to learn about the owners and their transactions.
- LYRA THERAPEUTICS INC (LYRA) Stock Chart to make your own analysis
- LYRA THERAPEUTICS INC (LYRA) Latest news and press-releases to stay up to date.
Does LYRA THERAPEUTICS INC (LYRA) stock pay dividends?
LYRA does not pay a dividend.
When does LYRA THERAPEUTICS INC (LYRA) report earnings?
LYRA THERAPEUTICS INC (LYRA) will report earnings on 2025-11-10, after the market close.
What is the Price/Earnings (PE) ratio of LYRA THERAPEUTICS INC (LYRA)?
LYRA THERAPEUTICS INC (LYRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-28.51).
What is the Short Interest ratio of LYRA THERAPEUTICS INC (LYRA) stock?
The outstanding short interest for LYRA THERAPEUTICS INC (LYRA) is 3.31% of its float. Check the ownership tab for more information on the LYRA short interest.
LYRA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to LYRA. When comparing the yearly performance of all stocks, LYRA is a bad performer in the overall market: 81.16% of all stocks are doing better.
LYRA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LYRA. While LYRA seems to be doing ok healthwise, there are quite some concerns on its profitability.
LYRA Financial Highlights
Over the last trailing twelve months LYRA reported a non-GAAP Earnings per Share(EPS) of -28.51. The EPS increased by 63.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -73.87% | ||
| ROE | -2394.33% | ||
| Debt/Equity | 0 |
LYRA Forecast & Estimates
9 analysts have analysed LYRA and the average price target is 23.46 USD. This implies a price increase of 233.95% is expected in the next year compared to the current price of 7.025.
For the next year, analysts expect an EPS growth of 87.06% and a revenue growth -50.07% for LYRA